New strategies in chronic lymphocytic leukemia: shifting treatment paradigms
about
The biology behind B-cell lymphoma 2 as a target in chronic lymphocytic leukemiaThe shrinking role of chemotherapy in the treatment of chronic lymphocytic leukemia.Idelalisib: A Novel PI3Kδ Inhibitor for Chronic Lymphocytic Leukemia.Janus and PI3-kinases mediate glucocorticoid resistance in activated chronic leukemia cells.A phase 1 clinical trial of flavopiridol consolidation in chronic lymphocytic leukemia patients following chemoimmunotherapyFactors involved in CLL pathogenesis and cell survival are disrupted by differentiation of CLL B-cells into antibody-secreting cells.Emerging immunological drugs for chronic lymphocytic leukemia.Pharmacodynamic considerations of small molecule targeted therapy for treating B-cell malignancies in the elderly.Chronic lymphocytic leukemia (CLL)-Then and now.Bendamustine hydrochloride in patients with B-cell malignancies who have comorbidities - is there an optimal dose?Combination with vorinostat overcomes ABT-263 (navitoclax) resistance of small cell lung cancer.Therapeutic CD94/NKG2A blockade improves natural killer cell dysfunction in chronic lymphocytic leukemia.Dynamic pre-BCR homodimers fine-tune autonomous survival signals in B cell precursor acute lymphoblastic leukemia.PPAR-delta promotes survival of chronic lymphocytic leukemia cells in energetically unfavorable conditions.Increased FcγRIIB dominance contributes to the emergence of resistance to therapeutic antibodies in chronic lymphocytic leukaemia patients.Chronic lymphocytic leukaemia
P2860
Q28075683-36A4C91C-0D8A-4E86-AC00-06278DA101BAQ30243968-B4E68ADA-CBFA-4106-993B-D6F885EB2237Q33424543-5C433621-017C-4D5F-B820-8EBA975E3904Q36118340-CCF88E53-2524-46A4-9F6B-B07F7D6287F6Q37168430-4763FBA4-BBF8-4023-AE51-CE98BEF3B0B1Q38298483-D518DE07-9EBC-4E44-B24A-714FB7011D31Q38543771-5E14A6D0-3C1A-4352-8901-55D608416925Q38544216-3D3EDBC6-7831-44E2-9991-6477054B817BQ38675358-B9C97771-7229-4B7D-9C44-3DEF43A4510CQ38700745-97C98ECE-6635-4C43-8568-615752B69D50Q38819019-4E7F6BBD-353D-4B9B-9DDD-15D54626DEE3Q41625025-FA3D1220-423B-4595-9697-52429CE7BBE9Q46364067-CBDD801B-0F48-4B04-952D-6FB4AD618B92Q51219604-ADB2A738-BDBE-4314-9A01-835741546C30Q51386372-DCF9F93E-AA27-4C73-94B3-7765AAD075DEQ56270980-65A6638B-F0D6-42CD-8606-5983CFC0B0F8
P2860
New strategies in chronic lymphocytic leukemia: shifting treatment paradigms
description
2014 nî lūn-bûn
@nan
2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
New strategies in chronic lymphocytic leukemia: shifting treatment paradigms
@ast
New strategies in chronic lymphocytic leukemia: shifting treatment paradigms
@en
New strategies in chronic lymphocytic leukemia: shifting treatment paradigms
@nl
type
label
New strategies in chronic lymphocytic leukemia: shifting treatment paradigms
@ast
New strategies in chronic lymphocytic leukemia: shifting treatment paradigms
@en
New strategies in chronic lymphocytic leukemia: shifting treatment paradigms
@nl
prefLabel
New strategies in chronic lymphocytic leukemia: shifting treatment paradigms
@ast
New strategies in chronic lymphocytic leukemia: shifting treatment paradigms
@en
New strategies in chronic lymphocytic leukemia: shifting treatment paradigms
@nl
P2860
P1476
New strategies in chronic lymphocytic leukemia: shifting treatment paradigms
@en
P2093
F. T. Awan
J. C. Byrd
P2860
P304
P356
10.1158/1078-0432.CCR-14-1889
P407
P577
2014-12-01T00:00:00Z